Formulation of Topical Naltrexone for the Treatment of Dry EyeID# 2022-5369
Researchers have introduced a novel technology centered around the use of naltrexone along with a suitable carrier, as an effective treatment for dry eye. This innovation sets specific dosage limits for these compounds, refining the composition of the carrier and enhancing treatment regimens. Current therapies offer temporary relief and can be expensive, whereas this new therapy surpasses the drawbacks of over-the-counter lubricants, giving the possibility for improved dry eye management, providing patients with more effective and long-lasting solutions to alleviate dry eye discomfort.
Application & Market Utility
Dry eye is an extremely common condition that affects approximately 4.9 million Americans that are 50 and older. Currently on the market are the commonly used over-the-counter lubricants which offer ineffective treatments. The inventors in response have created an alternative compound that effectively combats the shortcomings of said lubricants. The current market for products treating dry eye is estimated to be approximately $6.5 billion dollars as of 2022. It is projected that the market for dry eye will grow and reach approximately $12.3 billion by 2032.
Naltrexone treatment for dry eye is a previously unexplored method. For that reason, the next step for this invention would be to license the technology to a company focusing on topical treatment of dry eye.